A dosage range of 100 to 200 μg of anti-TNFR2 was used for treating mouse tumor models [40,41], while there was no remarkable antitumor effect when suboptimal dose (20 μg) was administered [42]. This evidence concerns the gene TNFRSF1B and neoplasm.